​

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MDGL Stock Forecast

Madrigal Pharmaceuticals stock forecast is as follows: an average price target of $315.75 (represents a 7.61% upside from MDGL’s last price of $293.41) and a rating consensus of 'Buy', based on 12 wall street analysts offering a 1-year stock forecast.

MDGL Price Target

The average price target for Madrigal Pharmaceuticals (MDGL) is $315.75 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $410.00 to $111.00. This represents a potential 7.61% upside from MDGL's last price of $293.41.

MDGL Analyst Ratings

Buy

According to 12 Wall Street analysts, Madrigal Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for MDGL stock is 0 'Strong Buy' (0.00%), 9 'Buy' (75.00%), 3 'Hold' (25.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Madrigal Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 29, 2024Yasmeen RahimiPiper Sandler$336.00$221.7551.52%14.52%
May 09, 2024Ed AcreH.C. Wainwright$390.00$208.0487.46%32.92%
Mar 19, 2024Liisa BaykoEvercore ISI$405.00$265.6852.44%38.03%
Mar 15, 2024Eliana MerleUBS$410.00$270.3751.64%39.74%
Mar 15, 2024Akash TewariJefferies$400.00$270.3747.95%36.33%
Mar 15, 2024Ed AcreH.C. Wainwright$425.00$270.3757.19%44.85%
Mar 15, 2024Jonathan WollebenJMP Securities$397.00$270.3746.84%35.31%
Mar 15, 2024Mayank MamtaniB.Riley Financial$270.00$270.37-0.14%-7.98%
Jan 05, 2023JMP Securities$390.00$274.4842.09%32.92%
Dec 21, 2022UBS$337.00$257.1231.07%14.86%
Dec 20, 2022H.C. Wainwright$225.00$251.50-10.54%-23.32%
Dec 20, 2022Oppenheimer$250.00$242.003.31%-14.79%
Dec 20, 2022Goldman Sachs$375.00$234.8359.69%27.81%
Dec 20, 2022JMP Securities$312.00$234.8332.86%6.34%
Dec 20, 2022Leerink Partners$315.00$234.8334.14%7.36%
Aug 06, 2021Matthew LuchiniBMO Capital$111.00$90.9522.05%-62.17%
May 20, 2021Andrea TanGoldman Sachs$195.00$129.7750.27%-33.54%
May 06, 2021Derek ArchilaWells Fargo$130.00$126.712.60%-55.69%

The latest Madrigal Pharmaceuticals stock forecast, released on May 29, 2024 by Yasmeen Rahimi from Piper Sandler, set a price target of $336.00, which represents a 51.52% increase from the stock price at the time of the forecast ($221.75), and a 14.52% increase from MDGL last price ($293.41).

Madrigal Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts--8
Avg Price Target--$379.13
Last Closing Price$293.41$293.41$293.41
Upside/Downside-100.00%-100.00%29.22%

In the current month, the average price target of Madrigal Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Madrigal Pharmaceuticals's last price of $293.41. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jul 16, 2024JMP SecuritiesOutperformOutperformHold
Jun 28, 2024Cantor FitzgeraldNeutralInitialise
Jun 10, 2024Wolfe ResearchOutperformInitialise
Jun 06, 2024CitigroupBuyBuyHold
May 29, 2024Piper SandlerOverweightOverweightHold
May 10, 2024B. RileyNeutralNeutralHold
May 09, 2024H.C. WainwrightBuyBuyHold
Apr 22, 2024Bank of America SecuritiesUnderperformInitialise
Dec 21, 2022UBSBuyBuyHold
Dec 20, 2022OppenheimerBuyBuyHold
Dec 20, 2022OppenheimerOutperformOutperformHold
Dec 20, 2022SVB LeerinkOutperformOutperformHold
Dec 20, 2022Goldman SachsBuyBuyHold
Dec 20, 2022JMP SecuritiesMarket OutperformMarket OutperformHold
Dec 19, 2022Raymond JamesMarket PerformUpgrade
Jul 08, 2022B. RileyBuyDowngrade
Jun 27, 2022SVB LeerinkMarket OutperformMarket OutperformHold

Madrigal Pharmaceuticals's last stock rating was published by JMP Securities on Jul 16, 2024. The company gave MDGL a "Outperform" rating, the same as its previous rate.

Madrigal Pharmaceuticals Financial Forecast

Madrigal Pharmaceuticals Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 19Mar 17Mar 16Mar 14Mar 13Mar 12Mar 11Mar 10Mar 09Mar 08
Revenue-----------------$147.00K$1.14M$4.02M$4.51M-
Avg Forecast$431.20M$216.05M$166.19M$132.95M$161.32M$136.78M$118.51M$96.98M$87.50M$34.60M$4.25M$114.77K$5.69M$2.95M$1.82M$5.45M$3.46M$91.32K$1.13M$3.50M$3.50M$1.29M
High Forecast$509.85M$255.45M$196.50M$157.20M$190.75M$161.73M$140.12M$121.41M$103.31M$40.91M$4.25M$114.88K$6.82M$3.54M$2.19M$6.54M$4.15M$109.59K$1.36M$4.20M$4.20M$1.55M
Low Forecast$329.99M$165.34M$127.18M$101.75M$123.46M$104.68M$90.69M$71.42M$49.75M$26.48M$4.25M$114.65K$4.55M$2.36M$1.46M$4.36M$2.77M$73.06K$907.00K$2.80M$2.80M$1.03M
# Analysts444433359474128101712201314813
Surprise %-----------------1.61%1.01%1.15%1.29%-

Madrigal Pharmaceuticals's average Quarter revenue forecast for Mar 13 based on 12 analysts is $3.46M, with a low forecast of $2.77M, and a high forecast of $4.15M. MDGL's average Quarter revenue forecast represents a 2251.67% increase compared to the company's last Quarter revenue of $147.00K (Mar 12).

Madrigal Pharmaceuticals EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 19Mar 17Mar 16Mar 14Mar 13Mar 12Mar 11Mar 10Mar 09Mar 08
# Analysts444433359474128101712201314813
EBITDA------------$-15.05M$-6.00M$-6.40M$-22.74M$-20.16M$-14.82M$-10.53M$-8.79M$-22.71M-
Avg Forecast------------$-17.90M$-7.70M$-12.80M$-23.26M$-17.70M$-13.41M$-10.84M$-7.54M$-16.21M$-16.89M
High Forecast------------$-14.32M$-6.16M$-10.24M$-18.61M$-14.16M$-10.73M$-8.67M$-6.03M$-12.97M$-13.51M
Low Forecast------------$-21.49M$-9.23M$-15.36M$-27.91M$-21.24M$-16.10M$-13.01M$-9.04M$-19.46M$-20.27M
Surprise %------------0.84%0.78%0.50%0.98%1.14%1.10%0.97%1.17%1.40%-

undefined analysts predict MDGL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Madrigal Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Madrigal Pharmaceuticals Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 19Mar 17Mar 16Mar 14Mar 13Mar 12Mar 11Mar 10Mar 09Mar 08
# Analysts444433359474128101712201314813
Net Income------------$-15.08M$-6.00M$-6.52M$-23.56M$-20.73M$-15.05M$-11.40M$-9.31M$-23.50M-
Avg Forecast$163.96M$-13.92M$-45.88M$-67.19M$-43.88M$-58.97M$-70.61M$-83.20M$-98.14M$-146.74M$-163.89M$-136.67M$-14.92M$-7.70M$-13.05M$-24.10M$-18.20M$-13.62M$-11.74M$-7.98M$-16.78M$-17.56M
High Forecast$202.84M$-9.67M$-31.88M$-46.69M$-30.49M$-40.98M$-49.07M$-66.61M$-83.62M$-101.97M$-113.88M$-94.97M$-11.94M$-6.16M$-10.44M$-19.28M$-14.56M$-10.90M$-9.39M$-6.38M$-13.42M$-14.05M
Low Forecast$113.93M$-17.22M$-56.76M$-83.13M$-54.29M$-72.95M$-87.36M$-99.59M$-110.92M$-181.54M$-202.75M$-169.08M$-17.91M$-9.23M$-15.66M$-28.92M$-21.84M$-16.35M$-14.09M$-9.57M$-20.14M$-21.07M
Surprise %------------1.01%0.78%0.50%0.98%1.14%1.10%0.97%1.17%1.40%-

Madrigal Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MDGL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Madrigal Pharmaceuticals SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 19Mar 17Mar 16Mar 14Mar 13Mar 12Mar 11Mar 10Mar 09Mar 08
# Analysts444433359474128101712201314813
SG&A------------$5.75M$1.70M$3.04M$5.32M$3.88M$2.65M$2.67M$3.09M$4.07M-
Avg Forecast------------$5.69M$2.17M-$5.45M$3.41M--$2.65M$2.91M-
High Forecast------------$6.82M$2.61M-$6.54M$4.09M--$3.17M$3.49M-
Low Forecast------------$4.55M$1.74M-$4.36M$2.72M--$2.12M$2.32M-
Surprise %------------1.01%0.78%-0.98%1.14%--1.17%1.40%-

Madrigal Pharmaceuticals's average Quarter SG&A projection for Mar 24 is -, based on 4 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to MDGL last annual SG&A of $5.75M (Mar 19).

Madrigal Pharmaceuticals EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Mar 19Mar 17Mar 16Mar 14Mar 13Mar 12Mar 11Mar 10Mar 09Mar 08
# Analysts444433359474128101712201314813
EPS------------$-0.98$-0.50$-1.75$-9.80$-10.50$-9.45$-9.45$-8.40$-24.15-
Avg Forecast$7.54$-0.64$-2.11$-3.09$-2.02$-2.71$-3.25$-3.83$-4.51$-6.75$-7.54$-6.29$-1.00$-1.12$-2.10$-10.26$-8.22$-7.81$-10.03$-6.30$-13.41$-18.02
High Forecast$9.33$-0.44$-1.47$-2.15$-1.40$-1.88$-2.26$-3.06$-3.85$-4.69$-5.24$-4.37$-1.00$-0.89$-1.68$-8.21$-6.58$-6.25$-8.02$-5.04$-10.73$-14.42
Low Forecast$5.24$-0.79$-2.61$-3.82$-2.50$-3.35$-4.02$-4.58$-5.10$-8.35$-9.32$-7.78$-1.00$-1.34$-2.52$-12.31$-9.86$-9.37$-12.04$-7.56$-16.09$-21.62
Surprise %------------0.98%0.45%0.83%0.96%1.28%1.21%0.94%1.33%1.80%-

According to undefined Wall Street analysts, Madrigal Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MDGL previous annual EPS of $NaN (undefined).

Madrigal Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.52$70.0013361.54%Buy
INZYInozyme Pharma$2.94$16.00444.22%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
PLRXPliant Therapeutics$14.37$35.50147.04%Buy
MREOMereo BioPharma Group$3.40$8.00135.29%Buy
STOKStoke Therapeutics$12.10$26.50119.01%Buy
VKTXViking Therapeutics$46.70$97.80109.42%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
IOVAIovance Biotherapeutics$7.81$12.4058.77%Buy
ETNB89bio$7.98$12.0050.38%Buy
SRPTSarepta Therapeutics$125.76$187.2048.85%Buy
ACLXArcellx$82.03$111.6036.05%Buy
KRYSKrystal Biotech$169.04$210.3324.43%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy
PTCTPTC Therapeutics$47.02$48.002.08%Hold
TGTXTG Therapeutics$33.57$23.75-29.25%Buy

MDGL Forecast FAQ

Is Madrigal Pharmaceuticals a good buy?

Yes, according to 12 Wall Street analysts, Madrigal Pharmaceuticals (MDGL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 75.00% of MDGL's total ratings.

What is MDGL's price target?

Madrigal Pharmaceuticals (MDGL) average price target is $315.75 with a range of $111 to $410, implying a 7.61% from its last price of $293.41. The data is based on 12 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Madrigal Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for MDGL stock, the company can go up by 7.61% (from the last price of $293.41 to the average price target of $315.75), up by 39.74% based on the highest stock price target, and down by -62.17% based on the lowest stock price target.

Can Madrigal Pharmaceuticals stock reach $400?

MDGL's highest twelve months analyst stock price target of $410 supports the claim that Madrigal Pharmaceuticals can reach $400 in the near future.

What are Madrigal Pharmaceuticals's analysts' financial forecasts?

Madrigal Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $513.6M (high $614.02M, low $390.25M), average EBITDA is $0 (high $0, low $0), average net income is $-257M (high $-187M, low $-314M), average SG&A $0 (high $0, low $0), and average EPS is $-11.803 (high $-8.606, low $-14.448). MDGL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $946.4M (high $1.12B, low $724.25M), average EBITDA is $0 (high $0, low $0), average net income is $36.97M (high $114.6M, low $-43.176M), average SG&A $0 (high $0, low $0), and average EPS is $1.7 (high $5.27, low $-1.985).

Did the MDGL's actual financial results beat the analysts' financial forecasts?

In terms of the last quarterly report (Mar 2012), Madrigal Pharmaceuticals's revenue was $147K, beating the average analysts' forecast of $91.32K by 60.97%. The company's EBITDA was $-14.821M, beating the average prediction of $-13.413M by 10.50%. Madrigal Pharmaceuticals's net income was $-15.051M, beating the average estimation of $-13.621M by 10.50%. The company's SG&A was $2.65M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-9.45, beating the average prediction of $-7.81 by 21.00%